Full-Time
$14.81 - $23/hr
Minneapolis, MN, USA
In Person
| , |
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Toledo, Ohio
Founded
1967
Help us improve and share your feedback! Did you find this helpful?
People at NAMSA who can refer or advise you
Remote Work Options
TOLEDO, Ohio, March 3, 2025 /PRNewswire/ -- NAMSA, a leading US based MedTech testing, clinical and regulatory consulting firm, announced that it finalized its acquisition of WuXi AppTec's US medical device testing operations on February 28.The acquisition brings together two of the most trusted names in medical device biological safety testing, serving more than 4,000 manufacturers worldwide.Lisa Olson, NAMSA Senior Vice President of Global Laboratory Services notes: "Together, we now have unmatched scientific expertise in biocompatibility, microbiology, preclinical and extractables and leachables testing. With the addition of WuXi AppTec medical device testing facilities in the US, we now have more scientists, more lab capacity and more expertise with a wider variety of medical devices than any other company. This combined expertise will continue to enable our work with clients to develop testing and consulting strategies tailored to their specific device and regulatory pathways."NAMSA has been expanding its reach in recent years as it continues to diversify its offering beyond biological safety testing. Since 2021, the company has acquired no fewer than six companies focused on preclinical or clinical research, making NAMSA one of the leading MedTech focused CROs. Brian Smith, NAMSA's recently appointed CEO noted: "This acquisition is part of our larger strategy to broaden our service offering and solidify our position as the go-to resource for manufacturers bringing new life-saving technologies to market while upholding the same high standards of client focused service you have come to expect from NAMSA."About NAMSAHelping medical device Sponsors improve healthcare since 1967, NAMSA is a leading global MedTech testing, clinical and regulatory consulting firm. With a deep pool of testing, clinical and regulatory experts, and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development
TOLEDO, Ohio, Feb. 24, 2025 /PRNewswire/ -- NAMSA, a world-leading MedTech testing, clinical and regulatory consulting firm, announced today that Brian P. Smith has taken on the role of NAMSA's next Chief Executive Officer. Most recently, Brian served as the Chairman and Chief Executive Officer of Ad-Tech Medical Instrument Corp., a leading US neuro-diagnostic company.Andre-Michel Ballester, NAMSA's outgoing CEO, will transition back into his role as a managing partner of ARCHIMED, the healthcare-focused global private equity firm that holds a majority stake in NAMSA.Ballester led the search for a new CEO and notes: "Brian is globally recognized as a respected healthcare executive, having served in various leadership roles over the past 15 years as a Board Member, Operating Partner, Chairman of the Board, and Chief Executive Officer with extensive experience in operational, commercial, and innovation strategies. Brian's international experience, having lived and worked in Hong Kong, Shanghai, and Singapore, will be invaluable as we continue to expand our global footprint."Smith adds: "I am thrilled to join an organization with the history, reputation, and contribution to improved patient outcomes that NAMSA has repeatedly demonstrated for decades. I look forward to making my own contribution to this ongoing success story."NAMSA recently announced that it had signed a definitive agreement to purchase the US medical device testing operations of WuXi AppTec
Under the agreement, NAMSA will acquire WuXi AppTec facilities in Minnesota and Georgia.
Japanese med tech leader Terumo announces strategic outsourcing partnership with Namsa.
NAMSA acquires german based CRI to expand clinical research and geographic reach across europe | business wire.